Open Biology: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
'''Open Biology''' | '''Open Biology''' | ||
Putting biological research, such as genome research, in the public domain. | |||
=Example= | |||
From an article in Forbes at | |||
http://www.forbes.com/2007/02/12/novartis-genes-diabetes-research-biz-cz_mh_0212novartis.html? | |||
"There was a time when drug giants tried to keep leads like that to themselves in an attempt to gain an advantage over their competitors. They paid lots of money for the privilege, too. In 1993, GlaxoSmithKline tied up with Human Genome Sciences to develop drugs based on genome data. Five years later, Bayer spent $465 million to get access to the genetic library being assembled by Millennium Pharmaceuticals. Neither collaboration has led to a marketed drug. | |||
But another requirement of making the leap from genes to drugs is making the research public--a step that will make it difficult for researchers elsewhere to patent any of this raw genetic information. | |||
Novartis isn't the only drug firm embracing this "give it away for free" mentality. Pfizer has promised to make available for free a swath of genetic information emerging from a three-year collaboration with the National Institutes of Health." | |||
(http://www.forbes.com/2007/02/12/novartis-genes-diabetes-research-biz-cz_mh_0212novartis.html?) | |||
=More Information= | |||
See our tag on Open Biology at http://del.icio.us/mbauwens/Open-Biology | |||
Biological Innovation for Open Society, at http://www.bios.net/daisy/bios/15 ; overview of 'Open Biology' developments, at http://www.wired.com/news/medtech/0,1286,66545,00.html; | Biological Innovation for Open Society, at http://www.bios.net/daisy/bios/15 ; overview of 'Open Biology' developments, at http://www.wired.com/news/medtech/0,1286,66545,00.html; | ||
"BIOS will soon launch an open-source platform that promises to free up rights to patented DNA sequences and the methods needed to manipulate biological material. Users must only follow BIOS' "rules of engagement," which are similar to those used by the open-source software community. | "BIOS will soon launch an open-source platform that promises to free up rights to patented DNA sequences and the methods needed to manipulate biological material. Users must only follow BIOS' "rules of engagement," which are similar to those used by the open-source software community." | ||
(http://www.wired.com/news/medtech/0,1286,66289,00.html?) | (http://www.wired.com/news/medtech/0,1286,66289,00.html?) | ||
| Line 17: | Line 38: | ||
[[Category:Education]] | [[Category:Education]] | ||
[[Category:Science]] | |||
Revision as of 04:20, 13 February 2007
Open Biology
Putting biological research, such as genome research, in the public domain.
Example
From an article in Forbes at http://www.forbes.com/2007/02/12/novartis-genes-diabetes-research-biz-cz_mh_0212novartis.html?
"There was a time when drug giants tried to keep leads like that to themselves in an attempt to gain an advantage over their competitors. They paid lots of money for the privilege, too. In 1993, GlaxoSmithKline tied up with Human Genome Sciences to develop drugs based on genome data. Five years later, Bayer spent $465 million to get access to the genetic library being assembled by Millennium Pharmaceuticals. Neither collaboration has led to a marketed drug.
But another requirement of making the leap from genes to drugs is making the research public--a step that will make it difficult for researchers elsewhere to patent any of this raw genetic information.
Novartis isn't the only drug firm embracing this "give it away for free" mentality. Pfizer has promised to make available for free a swath of genetic information emerging from a three-year collaboration with the National Institutes of Health." (http://www.forbes.com/2007/02/12/novartis-genes-diabetes-research-biz-cz_mh_0212novartis.html?)
More Information
See our tag on Open Biology at http://del.icio.us/mbauwens/Open-Biology
Biological Innovation for Open Society, at http://www.bios.net/daisy/bios/15 ; overview of 'Open Biology' developments, at http://www.wired.com/news/medtech/0,1286,66545,00.html;
"BIOS will soon launch an open-source platform that promises to free up rights to patented DNA sequences and the methods needed to manipulate biological material. Users must only follow BIOS' "rules of engagement," which are similar to those used by the open-source software community." (http://www.wired.com/news/medtech/0,1286,66289,00.html?)
This article explains why Open Biology is a good idea, also for security reasons, at http://www.worldchanging.com/archives/002893.html
The Open Lab initiative, http://bioinformatics.org